Ipsen Optimizes its 2025 Path and Accelerates in Oncology with ImCheck Therapeutics

Commercial results exceed expectations over nine months

Ipsen achieved a 12.1% rise in revenue at constant exchange rates during the first nine months of 2025, reaching 2.73 billion euros. This growth is observed across the company's three main therapeutic areas, with a notable increase of 101% for rare diseases, 9.5% for neuroscience, and 6.6% for oncology. The strong performance of Iqirvo, Bylvay, and Somatuline supports this trend, while portfolio diversification becomes increasingly critical in the face of heightened competition, particularly in the somatostatin analog segment. David Loew, CEO, emphasizes the « sustained growth of our three therapeutic areas and the growing contribution of our portfolio dedicated to rare liver diseases, » justifying the upward revision of annual forecasts.

Reassessed Outlook for the Fiscal Year and a Stronger Financial Model

Buoyed by its results from the first three quarters, the laboratory is raising its annual revenue growth target to around 10% at constant currency rate by 2025, compared to the initial forecast of over 7%. The expected increase in the operating margin, now anticipated to be around 35% of revenue, reflects budgetary discipline and the continuous improvement of the product mix. Ipsen anticipates a slower-than-expected decline in Somatuline sales and sees accelerated momentum in its more recent products, despite an unfavorable currency effect estimated at 3%. This guidance reassures the market about the company's ability to absorb generic competition while capitalizing on its innovations and maintaining strong visibility on the pipeline.

ImCheck Therapeutics: A Strategic Asset for the Oncology Portfolio

The announcement of the acquisition of ImCheck Therapeutics marks a strategic shift for Ipsen. With the addition of ICT01, a monoclonal antibody currently in Phase II trials for acute myeloid leukemia, Ipsen enhances its portfolio with what is considered a « first-in-class » molecule in immuno-oncology.

This move aligns with a forty-year presence in oncology and now expands into new indications in hematology. For investors, integrating a product in advanced development signals a potential growth driver and illustrates the group's commitment to addressing unmet medical needs while broadening its revenue diversification.